- Home
- ESPR vs SSBK Comparison
ESPR vs SSBK Comparison
Compare ESPR & SSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- SSBK
- Stock Information
- Founded
- ESPR 2008
- SSBK 2007
- Country
- ESPR United States
- SSBK United States
- Employees
- ESPR N/A
- SSBK N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- SSBK Commercial Banks
- Sector
- ESPR Health Care
- SSBK Finance
- Exchange
- ESPR Nasdaq
- SSBK Nasdaq
- Market Cap
- ESPR 305.0M
- SSBK N/A
- IPO Year
- ESPR 2013
- SSBK 2021
- Fundamental
- Price
- ESPR $0.89
- SSBK $35.53
- Analyst Decision
- ESPR Buy
- SSBK Buy
- Analyst Count
- ESPR 7
- SSBK 1
- Target Price
- ESPR $5.93
- SSBK $36.00
- AVG Volume (30 Days)
- ESPR 5.7M
- SSBK 41.8K
- Earning Date
- ESPR 05-06-2025
- SSBK 04-21-2025
- Dividend Yield
- ESPR N/A
- SSBK 1.01%
- EPS Growth
- ESPR N/A
- SSBK 6.02
- EPS
- ESPR N/A
- SSBK 3.80
- Revenue
- ESPR $259,574,000.00
- SSBK $99,026,000.00
- Revenue This Year
- ESPR $5.70
- SSBK $19.18
- Revenue Next Year
- ESPR N/A
- SSBK $7.05
- P/E Ratio
- ESPR N/A
- SSBK $9.36
- Revenue Growth
- ESPR 12.99
- SSBK 18.43
- 52 Week Low
- ESPR $0.82
- SSBK $24.86
- 52 Week High
- ESPR $3.94
- SSBK $39.16
- Technical
- Relative Strength Index (RSI)
- ESPR 36.95
- SSBK 63.53
- Support Level
- ESPR $0.93
- SSBK $34.44
- Resistance Level
- ESPR $1.11
- SSBK $35.37
- Average True Range (ATR)
- ESPR 0.10
- SSBK 0.74
- MACD
- ESPR 0.02
- SSBK 0.28
- Stochastic Oscillator
- ESPR 25.10
- SSBK 93.37
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.